New research arising from the Cancer Vaccine Program at the Beth Israel Deaconness Medical Center in Boston indicates that an anti-cancer vaccine derived from an acute myeloid leukemia patient's cells significantly increases the chance of long-term survival.
According to senior researcher Dr. David Avigan, "the vaccine has produced long-term remission for 70% of a small group of vaccinated patients with an average age of 63."
To read more about this study, click here.
No comments:
Post a Comment